Journal
JOURNAL OF MICROENCAPSULATION
Volume 33, Issue 5, Pages 401-411Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/02652048.2016.1202344
Keywords
Magnolol; polyketal microparticles; anti-inflammatory; pulmonary drug delivery; acute lung injury
Funding
- Taipei Medical University-National Taiwan University of Science and Technology Joint Research Programme [TMU-NTUST-102-09]
- National Science Council of Taiwan [NSC100-2221-E-011-014-]
Ask authors/readers for more resources
Magnolol has shown inhibitory effects on NO production and TNF-alpha production in lipopolysaccharide (LPS)-activated macrophages and LPS-induced acute lung injury; however, the poor solubility of magnolol has hindered its clinical success. In this study, magnolol-loaded microparticles were prepared via single emulsion method from a polyketal polymer, termed PK3. The particle sizes of magnolol-loaded PK3 microparticle is 3.73 +/- 0.41 mu m, and was suitable for phagocytosis by macrophages and pulmonary drug delivery. PK3 microparticles exhibited excellent biocompatibility both in vitro and in vivo. More importantly, intratracheal delivery of these magnolol-loaded microparticles significantly reduced the lung inflammatory responses at low dosage of magnolol (0.5mg/kg), and have great clinical potential in treating acute lung injury.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available